The entire world is looking for effective cancer therapies whose benefits would outweigh their toxicity. One way to reduce resistance to chemotherapy and its adverse effects is the so called targeted therapy, which targets specific molecules ("molecular targets") that play a critical role in cancer growth, progression, and metastasis. One such specific target are microtubules. In this review we address the current knowledge about microtubule-targeting agents or drugs (MTAs/MTDs) used in cancer therapy from their synthesis to toxicities. Synthetic and natural MTAs exhibit antitumor activity, and preclinical and clinical studies have shown that their anticancer effectiveness is higher than that of traditional drug therapies. Furthermore, MTAs involve a lower risk of adverse effects such as neurotoxicity and haemotoxicity. Several new generation MTAs are currently being evaluated for clinical use. This review brings updated information on the benefits of MTAs, therapeutic approaches, advantages, and challenges in their research.
MECHANISMS OF ACTION OF MTAs
MTAs act against mitosis by interacting with tubulins at different sites ( Figure 1) (6) and interfering with the spindle dynamics. According to the mechanism of action, they are traditionally divided in two major groups: microtubule-stabilising (MSAs) and microtubule destabilising agents (MDAs). MSAs, such as taxanes (8) , epothilones (9) , and laulimalide (10) promote and stabilise tubulin polymerisation, whereas MDAs do the opposite. They prevent tubulin polymerisation and promote depolymerisation. Disassembly promoters bind to either the colchicine domain at the intradimer interface between α-and β-tubulin or the vinca domain near the exchangeable GTP-binding site (E-site) on β-tubulin (11) . This group includes colchicines (12) , vinca alkaloids (13) , eribulin, nocodazole (14) , and combretastatin A-4 (CA-4) (11, 15) .
Regardless of different binding sites, most MTAs elicit remarkably similar effects on microtubules, especially at the lowest effective drug concentrations. Taxanes bind to polymerised microtubules at the inner surface of the β subunit and stimulate tubulin polymerisation (8) . Similarly, epothilones bind to the taxane pocket of β-tubulin (16) . Colchicine, in turn, binds tubulin and blocks polymerisation (12) . Vinca alkaloids (vinblastine, vincristine) cause depolymerisation by forming tubulin paracrystals (6) . Laulimalide and peloruside also bind to a non-taxane site between two β-tubulins and promote the assembly of microtubules (17, 18) by strongly modulating longitudinal interactions between tubulin dimers and moderately modulating lateral interactions (2) . Eribulin inhibits tubulin polymerisation by binding the interdimer interface or the β-tubulin subunit. It also sequesters tubulin monomers into non-functional aggregates (13) . Nocodazole interferes with the polymerisation of microtubules (14) .
STUDIES ON MTAs: FROM MOLECULE TO DRUG
Small organic molecules which disrupt microtubule/ tubulin dynamics have been used in cancer therapy for many years, and new small organic molecules with antitubulin activity are being studied and developed (19) .
Combretastatin A-4 derivatives
Combretastatin is a natural product isolated from Combretum caffeum grown in South Africa. CA-4 and its analogues (Figures 2 and 3) are potent antitumour agents with demonstrated biological activity (20) (21) (22) (23) . CA-4 has low water solubility, but this problem has been solved with water-soluble derivatives. Recent studies (24) report that CA-4 causes 90-99 % tumour necrosis, and phase III clinical trials with CA-4 evidence that CA-4P is effective and safe in the treatment of thyroid cancer (25) . Colchicines bind to β-tubulin in the outer surface of the microtubule; Vinca alkaloids bind to β-tubulin in the outer surface of the microtubule and to tubulin dimers;  Nocodazole binds to tubulin dimers; Eribulin binds to β-tubulin in the microtubule end and to tubulin dimers; ▲Laulimalide and peloruside bind to β-tubulin in the outer surface of the microtubule (laulimalide binding site);
Epothilone binds to β-tubulin in the outer surface of the microtubule (near the taxane-binding site); Combretastatin A4 binds to the colchicine-binding site
Colchicine derivatives
Colchicine is obtained from Colchicum autumnale by extraction. It strongly binds to tubulin and disturbs microtubule assembly dynamics. Due to its toxicity, research has been focused on less toxic colchicine derivatives ( Figure 4 ) (26, 27) .
Indole derivatives
In recent years, a number of pharmacological activity studies have been focused on compounds bearing indole structure and reported antitumour activity through inhibition of tubulin polymerisation. Indole has also provided one of the most important skeletons for CA-4 analogues (28) (29) (30) (31) (32) . Figure 5 shows some examples of MTAs with indole backbone (compounds 12-18) (33) (34) (35) (36) (37) (38) (39) .
Other MTAs
Heterocyclic compounds such as 5-flourouracil, methotrexate, doxorubicin, and daunorubicin exhibit anticancer properties and have always made the core of anticancer drugs (40) .
Flavonoids and isoflavonoids are natural oxygen heterocyclic compounds carrying a benzopyran-4-one building block. The biological activity of flavonoids and isoflavonoids changes with the position of the phenyl ring. Flavonoids have the benzopyran-4-one core with a phenyl ring at position 2, and isoflavonoids at position 3. Flavonoids with anticancer activity include baicalein and quercetin, which have a 2-arylbenzopyran-4-one pharmacophore group. Tambulin (3,5-dihydroxy-7,8dimethoxy-2-(4-methoxyphenyl)benzopyran-4-one) is isolated from the fruits of Zanthoxylum armatum and used as a starting material for the synthesis of alkyl amine derivatives ( Figure 6 , compound 19) (41) .
Shikonin is isolated from the root of Lithospermum erythrorhizon and has been used in Europe and Asia since antiquity (42) . This natural compound has many pharmacological properties, such as wound healing, antioxidant, antibacterial, anti-inflammatory, and antitumour (43) (44) (45) (46) (47) . Structural changes have been made to increase target specificity, since shikonin shows non-selective cytotoxic effects on normal cells. One such compound is chalcone-containing shikonin derivative (48) (Figure 6 These compounds were less haemolytic than standard drug doxorubicin (55) .
Metal-based drugs such as cisplatin have commonly been used in cancer therapy. However, due to severe toxicity of platinum drugs, research focus has shifted to the synthesis of new, less toxic drugs. An example is pyrazoline-based Karahalil There are also reports of the design, synthesis, and biological evaluations of novel 4-substituted 5-methylfuro[2,3-d] pyrimidines (58) . Compound 25 ( Figure 6 ) is an important candidate for further research and development. It is currently under preclinical evaluations.
NATURAL COMPOUNDS
Taxol, a taxanediterpenoid, is widely used in the treatment of a variety of cancers (breast, ovarian, lung, head, and neck) (5, 60) . Taxanes promote tubulin stabilisation by straightening GDP-tubulin protofilaments into a conformation resembling GTP-tubulin (61, 62) .
So far, more than 400 taxanes have been isolated from several Taxus species (63) Figure 7 ) identified in Taxus wallichiana var. mairer (64) . Their antitumor activities were evaluated in different cancer lines (MCF-7, A549, and 3-AO). Compound 28 showed a significant antitumor activity on the MCF-7 cell line, with anticancer effect similar to taxol, which was used as positive control. In fact, compound 28 has been reported as a promising anticancer agent in breast cancer therapy. Compounds 26, 27, and 29 showed lower cytotoxicity than paclitaxel. All of them also exhibited a change/shift in microtubule dynamics similar to that of paclitaxel.
The microtubule cytoskeleton is the main target of paclitaxel (65) . This drug interacts with the β-subunit of polymerised microtubules and prevents their depolymerisation, which, in turn, results in mitotic arrest and apoptosis. Verma et al. (66) tried to identify a potent β-tubulin inhibitor using experimental and in silico approaches. For this purpose, compounds were extracted from Cassia fistula and their structure identified by GC-MS. Subsequently, oral bioavailability, toxicity, and docking studies resulted in one promising inhibitor molecule, namely Hop-22(29)-en-3. beta-ol ( Figure 8 ). The results of in silico studies suggest that it binds effectively to both the native and mutant β-tubulin. Its bioavailability was significantly higher than that of paclitaxel. However, these results need confirmation from experimental findings.
Searching the Naturally Occurring Plant-based Anticancer Compound-Activity-Target (NPACT) database, Verma et al. (66) identified 1574 alkaloids with anticancer potential. Their pharmacokinetics and toxicity, binding efficiency, binding affinity of the docked complex, and metabolising capacity were evaluated by several computer programs. The results of these computational analyses suggest, for the first time, that isostrychnine isolated from Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy Arh Hig Rada Toksikol 2019;70:160-172
Figure 6 Miscellaneous derivatives synthesised and evaluated as MTAs
Strychnosnux-vomica might have an inhibitory potential against β-tubulin, but this has yet to be confirmed experimentally.
Stillingias anguinolenta is an endemic Mexican medical plant with many unusual cyclic organic compounds (67) . About 30 Stillingia species are used as folk medicines for different purposes in America. In a recent study, Pfeffer et al. (68) reported inhibitory activity on kinesin-5 mitotic motor molecules by tonantzitlolone A (Figure 9 , compound 30), a diterpene isolated from Stillingias anguinolenta, and by its synthetic enantiomer (compound 33). Both promote microtubule polymerisation by reducing the attachment of kinesin-5 molecules to microtubules, increasing, in turn, the growth rate and decreasing the mitotic catastrophe frequency. The synthetic enantiomer showed a stronger inhibitory effect than the natural compound (IC 50~4 4.5 mmol/L versus IC 50~1 47 mmol/L, respectively). This inhibitory effect is related to the chemical modification of the parent molecule responsible for the enhanced antiproliferative effect of the natural compound tonantzitlolone A.
Magnolol, a hydroxylated biphenyl compound, is isolated from Magnolia officinalis (Magnoliaceae). It has muscle relaxant, antioxidant, anti-atherosclerotic, antiinflammatory, and antimicrobial effects. It is widely used as a folk remedy, especially in the Far East (69) . In recent years, it has been studied for anticancer effects (70) (71) (72) and reported to suppress metastasis in PC-3 human prostate carcinoma cells (70) . Its wnt/beta-catenin signalling pathway has been shown to mediate anticancer effect (71) . Magnolol has also been tested for cancer growth inhibition and shown to use the p53 pathway to suppress the development of cancer in gallbladder cancer cells (72) . Shen et al. (73) tested its effect on cellular microtubule polymerisation in human non-small lung cancer cells. Its IC 50 of approximately 5 µmol/L at 72 h makes it a promising candidate for the treatment of NSCLC.
Thalicthuberine, a phenanthrene alkaloid isolated from Hernandia albiflora (Hernandiaceae), is known for its antimicrobial activity (74). Levrier et al. (75) examined its antimitotic activity in prostate (PC-3) and cervical cancer (HeLa) cells and established respective IC 50 of 0.7 and 2.5 mmol/L. This promising agent did not directly inhibit tubulin polymerisation, but it destroyed cellular tubulin polymers and suppressed mitotic spindle dynamics.
6α-acetoxyanopterine (6-AA) is one of the anopterine analogues isolated from the Australian endemic tree Anopterus macleayanus. Levrier et al. (76) reported that 6-AA inhibited cell growth in prostate cell lines (IC 50 =3.1-11. 5 nmol/L). The same authors compared 6-AA activity with well-known microtubule inhibitors such as taxanes, vinca alkaloids, and 2-methoxyestradiol (2ME2) ( Figure 10) to find a number of promising effects (77) . At low, nanomolar, concentrations Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy Arh Hig Rada Toksikol 2019;70:160-172
Figure 7
Structures of N-debenzoyl-N-methyl-N-heptanoyl-taxol [27] , N-debenzoyl-N-methyl-N-octanoyl-taxol [28] , N-debenzoyl-Nmethyl-N-[4-methylhexanoyl]-axol [29] , Structures of tonantzitlolone A [30] and B [31] , and schematic representation of the flexibilane backbone [32] , [ent]tonantzitlolone A [33] 6-AA caused a strong accumulation of androgen-sensitive human prostate adenocarcinoma (LNCaP) cells in mitosis [through increased levels of phospho-Ser10 histone 3 protein (PHH3), which is a marker of mitosis], severe mitotic spindle defects, and asymmetric cell divisions in both prostate and cervical cancer cells. 6-AA caused mitotic catastrophe and cell death by apoptosis due to cell accumulation in the G2/M phase and deregulation of mitotic pathways. It also turned out to be a reversible microtubuledestabilising molecule at nanomolar concentrations, which, unlike vinca alkaloids and 2ME2, directly interacted with tubulin. Anticancer activity of polycyclic fatty acids contained in the plants of the genus Beilschmiedia has also been investigated. Williams et al. (78) collected plant materials in Nyanga (Gabon) and isolated one major component, neolignan iso-ocobullenone (Figure 11, compound 34) , and a number of other minor components ( Figure 11 ). Their cytotoxicity was screened with nuclear magnetic resonance (NMR) spectroscopy in NCI-H460 human lung cancer cells. Nine compounds had IC 50 over 20 μg/mL; 11 between 20 and 1 μg/mL, and only one, neolignan bifidenone ( Figure  11, compound 35) , had the IC 50 of 0.26 μmol/L. It also showed high antiproliferative activity in other cancer cells, including melanoma cell lines (A375, UACC-62, and SK-Mel-2) and the first NCI-60-cell line (IC 50 of 0.27 μmol/L), but not as high in the HCC-2998 colorectal cell line (IC 50 1.41 μmol/L). The most sensitive cell lines (IC 50 <0.1 μmol/L) turned out to be SR lymphoblasts and the MALME-3M and MDA-MB-435 melanoma cells.
Mukhtar et al. (79) reported that compound 35 inhibited tubulin polymerisation in a dose-dependent manner, arrested the cell cycle in the G2/M phase, and competed for the colchicine binding site.
ADVERSE EFFECTS OF MTAs

Haematological and gastrointestinal toxicity
Haematological toxicities of MTAs are usually related to neutropenia and myelosuppression. Myelosuppression results from the inhibition of rapidly dividing hematopoietic cells. Neutropenia is a more serious and usually doselimiting factor (80) .
Neurological toxicity
In addition to these adverse effects, clinical trials of a new epothilone class of MTAs (such as ixabepilone and sagopilone, analogous to taxanes) reported neurotoxicity, which diminished with lowering the dose, but this resulted in higher gastrointestinal toxicity (81) .
A major limitation to the use of MTAs is the high rate of neuropathy. Microtubule integrity is critical to normal neuronal function, and any microtubule dysfunction can lead to the development of some form of neuropathy through disruption of axonal transport and function (82) .
Peripheral neuropathy (PN) is a result of damage to peripheral nerves. It is a prominent dose-limiting adverse effect of paclitaxel (83) . This drug induces microtubule aggregation in the peripheral nervous system and interrupts axonal transport. Severe PN is less common in patients treated with docetaxel. However, there is no reliable objective method to assess PN, and PN diagnosis relies on clinical assessment, including physical examination (84) . CHALLENGES Although many MSAs have been applied extensively in clinical settings, the use of paclitaxel and other approved MSAs still presents many challenges, such a slow passage through the blood-brain barrier (BBB), poor solubility, toxicity, multidrug resistance, and low bioavailability. To overcome these challenges, many studies have focused on the structure-activity relationships. Investigations have improved some pharmaceutical properties of MTAs without significant problems (85) .
The main purpose of effective cancer treatment is to improve the specificity of therapy and to reduce adverse effects, especially those limiting the dose. For example, CA-4 monotherapy has raised doubts due to metabolic vulnerability and conformational instability (86) . It is important to reduce MTA toxicities against rapidly proliferating healthy cell compartments, such as haematological and gastrointestinal tissues.
Drug resistance is another major limitation. New targeted therapies and treatment approaches are being developed to overcome these limitations, including monoclonal antibodies (e. g. trastuzumab, bevacizumab), small molecule therapies (e. g. tyrosine kinase inhibitors, bortezomib), and drug conjugates. An example of the last Karahalil Figure 11 Structures of iso-ocobullenone [34] and bifidenone [35] group is vintafolide (EC 145), a water-soluble derivative of folic acid currently under evaluation in phase II clinical trials for the treatment of ovarian and lung cancer. It targets the upregulation of folate receptor (FR) expression. Folate receptors take three principal isoforms (α, β, and γ) with high affinity for folate-binding glycoproteins. FRα and FRβ strongly bind folic acid and its major circulating form 5-methyltetrahydrofolate (MeTHF). FRα is expressed at very high levels in ovarian, lung, kidney, and breast cancer, and its expression is a negative prognostic factor in patients with ovarian, breast, endometrial, uterine, and colorectal cancer (83) .
CURRENT CLINICAL TRIALS
Many new generation MTAs are still under evaluation for potential clinical use. Some of them have shown good tolerability and antitumor activity in specific cancers. ClinicalTrials.gov, a web-based resource established by the National Library of Medicine (NLM) of the National Institutes of Health (NIH), registered 5,662 ongoing and completed trials for various cancer treatments in 2018 ( Figure 12 ) (87).
Even though vinca alkaloids and taxanes have been known for 50 years, the scarcity of their natural sources (such as Pacific yew bark for taxol) is now being overcome by partial or total synthesis. However, total synthesis is still not the best option for development of drugs used in clinics. This situation is prevalent for many of the novel microtubule binding agents (88, 89) . Tubulin inhibitors are generally used in combination with other chemotherapeutic drugs. Paclitaxel is commonly used with gemcitabine for the treatment of metastatic adenocarcinoma of the pancreas, while cabazitaxel is used with prednisone for the treatment of metastatic, hormone-resistant prostate cancer.
SCREENING SYSTEMS FOR MTAs
Screening systems, such as phenotypic screening and Biological Similarity Ensemble Approach (BIOSEA), screen large libraries of chemical compounds to help drug industry develop effective and safe drugs through new approaches that would bring some advantage over the currently available methods used in drug research and development.
Phenotypic screening
Phenotypic screening is used in drug discovery to identify molecules (in animal models or cell-based assays) that can alter cell phenotype. It does not rely on knowing specific drug target or its hypothetical role in the disease. This type of screening can capture complex biological mechanisms that escape other approaches. It provides the understanding of cell signalling networks in disease development and decreases the amount of clinical trial failures by identifying factors contributing to unexpected activity, toxicities, and lack of efficacy.
The enthusiasm for phenotypic screening as an alternative to target-focused small-molecule discovery has increased dramatically over the last few years. Phenotypic screening is based on the results of animal, cell-based, and disease-related phenotypic assays, which determine the phenotype of a physiological system. It also includes all preclinical assay formats that use animals, cells, and biochemical pathways. The aim is to identify molecules with specific biological effects that alter microtubule stability (90) . Between 1999 and 2013; phenotypic screening has resulted in the discovery of 48 cancer drugs approved by the FDA, including three tubulin inhibitors ( Table 1) . Karahalil to streamline the phenotypic screening workflow. This statistical method identifies molecules able to reproduce a desired cellular phenotype based on biological similarity with compounds with such effect. This method provided an advantage over high-throughput screening assays and overcame problems such as highly incomplete and noisy compound bioactivity. It helped identify novel nanomolar inhibitors of cell division that reproduce the action of reference natural products.
The last two decades have seen a dramatic change in the understanding of interactions between small molecules and biological systems. It came with a major shift from reductionism to a more pragmatic view of living organisms as complex entities. At the same time phenotypic screening brought new challenges, such as the identification of mechanisms of action and effective targets responsible for these phenotypes. BIOSEA allows phenotypic screening without the need for information about the chemical structure of the target or associated ligands. One example is the Na-K-Cl cotransporter (NKCC1) (91) . Its cellular phenotype was characterised, and well-known natural products that inhibit cell division in two different ways, namely paclitaxel as a microtubule-stabilising agent and one tubulin polymerisation inhibitor, were selected as references to predict biologically similar compounds that could arrest the cell cycle.
In short, this statistical method establishes new relationships between targets and small molecules, which streamlines drug discovery.
CONCLUSION
Continuing research on the mechanisms of action of MTAs, discovery of new drugs, and search for novel therapy strategies helps to reduce their adverse effects, overcome resistance to cancer therapy, and provide more effective therapeutic options for cancer patients. This cannot be achieved without a better understanding of the molecular mechanisms of microtubule-dependent, tumour-specific pathways. 
